Hydroxychloroquine (HCQ) is an effective and typically well-tolerated anti-inflammatory medication, but retinal toxicity is a potential side effect.1 Current screening guidelines recommend baseline ophthalmic examination to rule out maculopathy and then yearly examination with visual field and optical coherence tomography after 5 years of HCQ use.1 The presence of HCQ retinopathy risk factors,2 such as HCQ duration ≥5 years, HCQ daily dose >5 mg/kg real body weight, tamoxifen use, or renal disease, should increase suspicion for retinopathy and may modify the retinopathy screening timeline.